Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-22-005237
Filing Date
2022-03-31
Accepted
2022-03-31 16:49:44
Documents
17
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A inzy-20211231.htm   iXBRL 10-K/A 104104
2 EX-23.1 inzy-ex23_1.htm EX-23.1 5526
3 EX-31.1 inzy-ex31_1.htm EX-31.1 10240
4 EX-31.2 inzy-ex31_2.htm EX-31.2 10657
  Complete submission text file 0000950170-22-005237.txt   1723950

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inzy-20211231.xsd EX-101.SCH 46076
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inzy-20211231_pre.xml EX-101.PRE 329014
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT inzy-20211231_cal.xml EX-101.CAL 36423
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT inzy-20211231_def.xml EX-101.DEF 197655
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inzy-20211231_lab.xml EX-101.LAB 439093
11 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20211231_htm.xml XML 11060
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39397 | Film No.: 22793570
SIC: 2834 Pharmaceutical Preparations